Search

Your search keyword '"Benafif, S"' showing total 73 results

Search Constraints

Start Over You searched for: Author "Benafif, S" Remove constraint Author: "Benafif, S"
73 results on '"Benafif, S"'

Search Results

1. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

2. The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

3. Body composition and lung cancer-associated cachexia in TRACERx

4. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

5. Genomic–transcriptomic evolution in lung cancer and metastasis

6. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

7. Antibodies against endogenous retroviruses promote lung cancer immunotherapy

8. The evolution of lung cancer and impact of subclonal selection in TRACERx

9. Copy number architectures define treatment-mediated selection of lethal prostate cancer clones

11. The evolution of lung cancer and impact of subclonal selection in TRACERx

12. Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe

13. The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening

14. 1575P Systemic anti-cancer therapy and metastatic cancer are independent mortality risk factors during two UK waves of the COVID-19 pandemic at University College London Hospital

15. Clinical portrait of the SARS-Cov-2 epidemic in European cancer patients

16. Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY)

21. 1671MO Provision of palliative care for patients with cancer and SARS-CoV-2 infection

22. Germline DNA repair gene mutations in young-onset prostate cancer cases in the UK: evidence for a more extensive genetic panel

23. Chapter Four - Genetics of prostate cancer and its utility in treatment and screening.

25. An update on PARP inhibitors for the treatment of cancer

26. Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls

31. 570 Poster - Neoadjuvant endocrine treatment and clinical outcome in ER positive breast cancer – a single UK cancer centre experience.

33. Clinical portrait of the SARS-CoV-2 epidemic in european patients with cancer

34. Entrectinib-Induced Myocarditis and Acute Heart Failure Responding to Steroid Treatment: A Case Report.

35. Out-of-hours admissions in patients treated with immune checkpoint inhibitors and their primary management with steroids.

36. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx.

37. Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genes.

38. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.

39. The evolution of lung cancer and impact of subclonal selection in TRACERx.

40. The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening.

41. Systemic Anti-Cancer Therapy and Metastatic Cancer Are Independent Mortality Risk Factors during Two UK Waves of the COVID-19 Pandemic at University College London Hospital.

42. Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer.

43. Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective.

44. Management of Late Relapses After Chemotherapy in Testicular Cancer: Optimal Outcomes with Dose-intense Salvage Chemotherapy and Surgery.

45. Cancer History and Systemic Anti-Cancer Therapy Independently Predict COVID-19 Mortality: A UK Tertiary Hospital Experience.

46. Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe.

47. Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY).

48. A Review of Prostate Cancer Genome-Wide Association Studies (GWAS).

49. Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls.

50. Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer.

Catalog

Books, media, physical & digital resources